Year: 2021

Ennoconn Announces Definitive Agreement to Acquire NCR Budapest Manufacturing Facility

Written by Customer Service on December 12, 2021. Posted in Mergers And Acquisitions.

NEW TAIPEI CITY, Taiwan, Dec. 12, 2021 (GLOBE NEWSWIRE) — Ennoconn Corporation (Taiwan Exchange / 6414.TW), a global leader in integrated cloud management services, Industrial IoT and embedded technology, today announced a definitive agreement to acquire NCR’s Budapest manufacturing facility, including physical assets, personnel, and the transfer of manufacturing responsibilities. This transaction allows Ennoconn Corporation, a financial subsidiary of Foxconn, to significantly expand their footprint in Europe by acquiring NCR’s World Class manufacturing, integration and assembly operations in Budapest. Ennoconn plans to continue to produce ATM, self-checkout (SCO) and point of sale (POS) solutions for NCR’s European Banking and Retail customer demand. “Ennoconn will utilize this facility and additional resources to advance manufacturing...

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs

Written by Customer Service on December 12, 2021. Posted in Public Companies.

Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional CAR T cells in vivo, demonstrating T cell-specific delivery and therapeutic function in animal models SEATTLE, Dec. 12, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, presented data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Saturday, December 11 to Tuesday, December 14, 2021, which highlighted further progress with key technologies supporting Sana’s in vivo and ex vivo CAR T cell programs. “The data presented at ASH showcase the progress we are making with Sana’s CAR T cell programs,” said...

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

Written by Customer Service on December 12, 2021. Posted in Public Companies.

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological DiseasesData presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation, strong safety profile and long duration of action Data support ongoing studies in patients with thalassemia and myelodysplastic syndrome and a new planned study in polycythemia vera12 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented additional positive data from the SLN124 healthy volunteer study at the 2021 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia (USA)....

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

Written by Customer Service on December 12, 2021. Posted in Public Companies.

— Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS — Objective responses were observed in patients with relapsed/refractory MDS that had progressed after prior hypomethylating agents — No exacerbation of cytopenias and no dose limiting toxicities observed in combination with azacitidine — ALX Oncology to Host Conference Call on December 13th at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Dec. 12, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination...

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

Written by Customer Service on December 12, 2021. Posted in Public Companies.

U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the blood‑brain barrier in preclinical models enabling potential dual development in oncology and autoimmune diseases of the central nervous system NX‑5948 reduces tumor burden and extends survival in a preclinical model of primary central nervous system lymphoma SAN FRANCISCO, Dec. 12, 2021 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the grant of a Clinical Trial Authorization (CTA) for NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase (BTK) and the second drug candidate in Nurix’s BTK degradation program. The authorization was granted by the U.K. Medicines &...

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

Written by Customer Service on December 12, 2021. Posted in Public Companies.

Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with Oxbryta Phase 1 study of inclacumab also presented at ASH supports best-in-class potential as a quarterly-dosed P-selectin inhibitor SOUTH SAN FRANCISCO, Calif., Dec. 12, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced positive results from real-world and long-term studies with Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD). A first-in-class oral, once-daily therapy, Oxbryta directly inhibits sickle hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. Results from a large retrospective analysis of 3,128 SCD patients treated...

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH

Written by Customer Service on December 12, 2021. Posted in Public Companies.

CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a three-stage, long-term development strategy for its base editing approach to treat sickle cell disease (SCD). The plan, and supportive data, are being presented during a Scientific Program Session oral presentation and two poster sessions at the 63rd American Society for Hematology (ASH) Annual Meeting & Exposition. SCD is a severe, hereditary monogenic blood disorder that alters the structure and function of oxygen-carrying hemoglobin in red blood cells and is caused by a single letter spelling error in the beta globin gene. To fully address SCD and support broad accessibility, Beam is deploying a stepwise strategy that includes advancements...

Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)

Written by Customer Service on December 11, 2021. Posted in Public Companies.

– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. Additionally, a published abstract in Blood reports on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma. NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed...

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Written by Customer Service on December 11, 2021. Posted in Public Companies.

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation rate due to adverse reactions demonstrated in 24-week primary analysis1Data support longer-term use of Scemblix in patients with chronic myeloid leukemia (CML) who have previously struggled with intolerance and resistance to at least two prior tyrosine kinase inhibitor treatments2-4Differentiated by novel mechanism of action, Scemblix is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket2-4Clinical development program continues, evaluating Scemblix across multiple treatment lines in CML2-19Basel, December 11, 2021 — Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib)...

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Written by Customer Service on December 11, 2021. Posted in Public Companies.

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in high-grade B-cell lymphoma (HGBL), formerly referred to as double-hit lymphoma (DHL), and chronic lymphocytic leukemia (CLL), in two presentations at the 63rd American Society of Hematology (ASH) Annual Meeting held December 11-14, 2021 in Atlanta GA. “The data presented at ASH show that VIP152 has increased selectivity...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals